These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 17545850)

  • 1. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
    Yoneda KY; Shelton DK; Beckett LA; Gandara DR
    J Thorac Oncol; 2007 Jun; 2(6):537-43. PubMed ID: 17545850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Kashiwabara K; Semba H; Fujii S; Tsumura S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
    Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
    J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
    Makris D; Scherpereel A; Copin MC; Colin G; Brun L; Lafitte JJ; Marquette CH
    BMC Cancer; 2007 Aug; 7():150. PubMed ID: 17683587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.
    Shi L; Tang J; Tong L; Liu Z
    Lung Cancer; 2014 Feb; 83(2):231-9. PubMed ID: 24332320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
    Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ
    J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib--a cohort study.
    Johkoh T; Sakai F; Kusumoto M; Arakawa H; Harada R; Ueda M; Kudoh S; Fukuoka M
    Clin Lung Cancer; 2014 Nov; 15(6):448-54. PubMed ID: 25043209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.
    Lind JS; Smit EF; Grünberg K; Senan S; Lagerwaard FJ
    J Thorac Oncol; 2008 Sep; 3(9):1050-3. PubMed ID: 18758310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer.
    Hirsch FR; Varella-Garcia M; Dziadziuszko R; Xiao Y; Gajapathy S; Skokan M; Lin M; O'Neill V; Bunn PA
    Clin Cancer Res; 2008 Oct; 14(19):6317-23. PubMed ID: 18829515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661).
    Atagi S; Katakami N; Yoshioka H; Fukuoka M; Kudoh S; Ogiwara A; Imai M; Ueda M; Matsui S
    Clin Lung Cancer; 2013 Jul; 14(4):407-17. PubMed ID: 23490546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC.
    Reck M
    Future Oncol; 2006 Feb; 2(1):47-51. PubMed ID: 16556072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
    Hotta K; Kiura K; Takigawa N; Yoshioka H; Harita S; Kuyama S; Yonei T; Fujiwara K; Maeda T; Aoe K; Ueoka H; Kamei H; Umemura S; Moritaka T; Segawa Y; Kawai H; Bessho A; Kato K; Tabata M; Tanimoto M
    J Thorac Oncol; 2010 Feb; 5(2):179-84. PubMed ID: 20101144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
    Tammaro KA; Baldwin PD; Lundberg AS
    J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials.
    Qi WX; Sun YJ; Shen Z; Yao Y
    J Chemother; 2015 Feb; 27(1):40-51. PubMed ID: 24724908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
    Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
    J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.
    Um SJ; Lee SK; Yang DK; Son C; Roh MS; Kim KN; Lee KN; Choi PJ
    Clin Respir J; 2009 Jul; 3(3):181-4. PubMed ID: 20298401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
    Togashi Y; Masago K; Hamatani Y; Sakamori Y; Nagai H; Kim YH; Mishima M
    Lung Cancer; 2012 Aug; 77(2):464-8. PubMed ID: 22579408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
    Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
    Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.
    Sandler A
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):17-22. PubMed ID: 14682119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.